Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …

Immune checkpoint inhibitors have emerged as a pillar in the management of advanced
malignancies. However, nonspecific immune activation may lead to immune-related adverse …

PURPOSE To update the guideline to include new anticancer agents, antiemetics, and
antiemetic regimens and to provide recommendations on the use of dexamethasone as a …

Background Concomitant medications, such as steroids, proton pump inhibitors (PPI) and
antibiotics, might affect clinical outcomes with immune checkpoint inhibitors. Methods We …

Immune checkpoint inhibitors (ICIs) can elicit toxicities by inhibiting negative regulators of
adaptive immunity. Sometimes, management of toxicities may require systemic …

Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …

Immune checkpoint inhibitors (ICIs) improve clinical outcomes in patients suffering from
different types of cancer. Liver toxicity is one of the immune-related adverse events …

Simple Summary Natural killer cells are innate cytotoxic lymphocytes that play a key role in
the anti-tumor immune response. In the tumor microenvironment, however, the effector …

The treatment of lung cancer has changed drastically in recent years owing to the advent of
immune checkpoint inhibitors (ICIs). A 1992 study reported that programmed cell death-1 …

In the past 10 years, a deeper understanding of the immune landscape of cancers, including
immune evasion processes, has allowed the development of a new class of agents. The …